<i>Ex vivo</i> activated memory T‐Iymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis‐diamminedichloroplatinum(II)

Gold, Jay E.; Masters, T.R.; Babbit, B.; Fine, Eugene M.; Weber, H.N.; Unger, Pamela; Leventhal, I.; Zippe, Craig D.; Osband, Michael E.

doi:10.1111/j.1464-410x.1995.tb07843.x

Cited by 4 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase of HLA antigens after incubation of tumor cells with CDDP was also demonstrated measuring the AC-81 adenocarcinoma-associated antigen on gastric cancer cell line KATO-3 [208], increase which resulted in increased susceptibility of the cancer cells to LAK cells and T-lymphocytes cytotoxicity. Similar effects of CDDP had been found by the same group using human soft tissue sarcoma cells [210] or renal cell carcinoma cells [211] as target tumor cells which were modified by CDDP and elicited increased memory T cells responses. Similar effects of CDDP had been found by the same group using human soft tissue sarcoma cells [210] or renal cell carcinoma cells [211] as target tumor cells which were modified by CDDP and elicited increased memory T cells responses.…”

Section: Anticancer Drugssupporting

confidence: 80%

“…Indeed at low doses Cyclophosphamide inhibited the growth of murine hepatoma MH129 in immunocompetent but not in immunodepleted mice and the inhibition did not occur in mice given CD4+CD25+ T cells [166]. In this study the interesting observation was made that the administration of low dose Cyclophosphamide was more effective in causing depletion of CD4+CD25+ cells when given after tumor inoculation than when given before tumor inoculation: as the authors stated [166], this finding is of relevance to clinical Phenylalinine mustard + [147,[188][189][190][191] Busulfan + + [148,169,[192][193][194] Nitrosoureas + + [148,[195][196][197][198][199][200][201][202] Cis Platinum + + [170,203,204,205,[206][207][208][209][210][211][212][213][214][215] Difluoromethylornithine + + [280][281][282][283][284][285] trials of chemotherapy and immunotherapy combinations. In this study the interesting observation was made that the administration of low dose Cyclophosphamide was more effective in causing depletion of CD4+CD25+ cells when given after tumor inoculation than when given ...…”

Section: Anticancer Drugsmentioning

confidence: 99%

“…The augmenting effects of CDDP on the antigenicity of murine and human tumors [207][208][209][210][211] have been mentioned above where the action of this drug was discussed. Very recently [307], it has been reported that DOX, and some related anthracyclines, but not Etoposide, Mitomycin C or other cytotoxic agents, augment the immunogenicity of mouse CT26 colon cancer and that this effect is mediated through the induction by drug of calreticulin or of a calreticulin-interacting chaperon by the anthracycline.…”

Section: Modifications Of Tumor Antigens By Drugsmentioning

confidence: 99%

See 2 more Smart Citations

Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics

Mihich

2007

CCTR

View full text Add to dashboard Cite

In the light of increasing knowledge on the regulation of the efferent and afferent branches of antitumor immunity, on tumor-induced imbalances of immune response and on tumor escape mechanisms, it seem important to review the information available on the immunomodulating effects of anticancer drugs and their possible exploitation in cancer therapeutics.The immunomodulation induced by several antitumor antibiotics is considered with particular emphasis on the effects of Doxorubicin and their therapeutic exploitation. The immunomodulating effects of anticancer drugs considered include those of cyclophosphamide and other alkylating agents, of 6-mercaptopurine and other antimetabolities, of Vinca alkaloida, Taxanes, Thalidomide, Gleevec and Difluoromethyl ornithine. The positive effects on tumor immunity are discussed with reference to their potential exploitation in the therapeutics. The effects of certain anticancer drugs on tumor antigen expression are also discussed as a mechanism by which these agents increase tumor immunogenicity with consequent advantages for therapeutic exploitation and vaccine effectiveness. The need for increased molecular and clinical studies of anticancer drugs-induced immunomodulation is emphasized.

show abstract

Section: Anticancer Drugssupporting

confidence: 80%

Section: Anticancer Drugsmentioning

confidence: 99%

Section: Modifications Of Tumor Antigens By Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics

Mihich

2007

CCTR

View full text Add to dashboard Cite

show abstract

“…We and others have previously confirmed that incubation of human breast, colorectal, and RCC tumor targets with CDDP can either enhance ex vivo lysis of these tumor targets by immune effector cells or allow enhanced ex vivo tumor recognition as measured by interferon-gamma (IFN-y) release [ 19,20,. For ALT-cells, this lysis was dependent on the presence of memory T-cells as depletion of the memory T-cell subset in murine and human TBH significantly reduced lysis of even CDDP-treated tumor targets [3,19,20]. Additionally, there have been reports demonstrating ex vivo lysis of sarcoma tumor targets by antitumor-specific T-cells derived from peripheral blood .…”

Section: Introductionmentioning

confidence: 99%

“…Aside from their direct tumoricidal effects, these agents also possess potent immunomodulatory properties both on the tumor cell itself as well as the adoptively transferred T-cells [9,10, 17,18]. We and others have previously confirmed that incubation of human breast, colorectal, and RCC tumor targets with CDDP can either enhance ex vivo lysis of these tumor targets by immune effector cells or allow enhanced ex vivo tumor recognition as measured by interferon-gamma (IFN-y) release [ 19,20,. For ALT-cells, this lysis was dependent on the presence of memory T-cells as depletion of the memory T-cell subset in murine and human TBH significantly reduced lysis of even CDDP-treated tumor targets [3,19,20].…”

Section: Introductionmentioning

confidence: 99%

Ex vivo activated memory t‐lymphocytes as adoptive cellular therapy of human soft‐tissue sarcoma targets with potentiation by Cis‐diamminedichloroplatinum (II)

Gold

Masters

Bloom

et al. 1995

Journal of Surgical Oncology

View full text Add to dashboard Cite

Autolymphocyte therapy (ALT) is tumor-specific, adoptive cellular therapy of neoplastic disease using nonspecific ex vivo activation of autologous peripheral blood lymphocytes (PBL), which are composed primarily of memory T-cells (ALT-cells) and are active in patients with metastatic renal cell carcinoma and melanoma. Ex vivo pretreatment of tumor target cells with certain chemotherapeutic agents can enhance susceptibility to lysis by antitumor lymphocytes. To determine if cis-diamminedichloroplatinum(II) (CDDP) enhances ex vivo antitumor cytotoxicity of ALT-cells and if this lysis is mediated by T- and/or NK-cells and is human leukocyte antigen (HLA)-restricted, human soft tissue sarcoma (STS) target cells were derived from primary and metastatic surgical specimens and were incubated with and without CDDP. ALT-cells were prepared from autologous PBL obtained prior to surgery. Primary (PSTS) and metastatic (MSTS) target cells from each group were labelled with chromium 51 (51Cr) and used as targets for ALT-cells, CD45-depleted ALT-cells, CD56 (NK)-depleted ALT-cells, and PBL in a standard (4-hour) and delayed (18-hour) 51Cr release assay. Interferon-gamma (IFN-gamma) release was measured as an indication of antitumor effect and recognition by the noncytolytic lymphocytes in ALT-cells. Primary tumor target cells incubated in CDDP showed enhanced lysis as measured by the 51Cr release assay compared to non-CDDP-treated controls. Metastatic tumor target cells showed less lysis than the primary targets, although this was enhanced by pretreating metastatic tumor targets with CDDP. Lysis of all tumor targets was significantly greater when ALT-cells were used as the effector cells rather than PBL. Depletion of memory T-cells abrogated ex vivo lysis. Depletion of NK cells (CD56+) affected ex vivo lysis of autologous targets during the 4-hour but not the 18-hour assay. Ex vivo ALT-cell lysis and IFN-gamma release against only the autologous tumor targets confirmed tumor-specificity in one patient. Restriction of ALT-cell lysis and IFN-gamma release against HLA-A2+ autologous and one allogeneic HLA-A2+ STS tumor target, but not other non-STS targets, was demonstrated in another patient. These data suggest that CDDP may help render STS susceptible to tumor-specific, immune-mediated attack and that the combination of ALT and CDDP may lead to effective tumor-specific chemoimmunotherapy in patients with metastatic STS.

show abstract